▶ 調査レポート

がん治療の世界市場:治療法別(化学療法、ターゲット療法、免疫療法(生物学的療法)、ホルモン療法、その他)、がんのタイプ別(血液がん、乳がん、前立腺がん、皮膚がん、呼吸器・肺がん、その他)、エンドユーザー別、地域別分析

• 英文タイトル:Global Cancer Therapy Market - Segmented by Therapy Type, Cancer Type, End User and Geography - Growth, Trends and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。がん治療の世界市場:治療法別(化学療法、ターゲット療法、免疫療法(生物学的療法)、ホルモン療法、その他)、がんのタイプ別(血液がん、乳がん、前立腺がん、皮膚がん、呼吸器・肺がん、その他)、エンドユーザー別、地域別分析 / Global Cancer Therapy Market - Segmented by Therapy Type, Cancer Type, End User and Geography - Growth, Trends and Forecast (2018 - 2023) / B-MOR-08099資料のイメージです。• レポートコード:B-MOR-08099
• 出版社/出版日:Mordor Intelligence / 2018年7月1日
• レポート形態:英文、PDF、115ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥454,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥481,500 (USD4,500)▷ お問い合わせ
  Corporate User¥936,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、がん治療の世界市場について調べ、がん治療の世界規模、市場動向、市場環境、治療法別(化学療法、ターゲット療法、免疫療法(生物学的療法)、ホルモン療法、その他)分析、がんのタイプ別(血液がん、乳がん、前立腺がん、皮膚がん、呼吸器・肺がん、その他)分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・がん治療の世界市場インサイト
・がん治療の世界市場環境
・がん治療の世界市場動向
・がん治療の世界市場規模
・がん治療の世界市場規模:治療法別(化学療法、ターゲット療法、免疫療法(生物学的療法)、ホルモン療法、その他)
・がん治療の世界市場規模:がんのタイプ別(血液がん、乳がん、前立腺がん、皮膚がん、呼吸器・肺がん、その他)
・がん治療の世界市場規模:エンドユーザー別
・がん治療の世界市場:地域別市場規模・分析
・がん治療の北米市場規模・予測
・がん治療のアメリカ市場規模・予測
・がん治療のヨーロッパ市場規模・予測
・がん治療のアジア市場規模・予測
・がん治療の日本市場規模・予測
・がん治療の中国市場規模・予測
・がん治療のインド市場規模・予測
・がん治療の韓国市場規模・予測
・関連企業情報・競争状況

The global cancer therapy market is expected to register a CAGR of 6.5% during the forecast period, 2018 to 2023. North America dominates the market, due to growing prevalence of cancer diseases and rapid adoption of new therapy and novel drugs in the region.

High Prevalence and Incidence of Cancer Disease Worldwide

Cancer is one of the leading causes of morbidity and mortality, globally. According to World Health Organization (WHO), in 2015, cancer was the second leading cause of death accounting for 8.8 million deaths, worldwide, and the number of new cancer cases is expected to rise by about 70% over the next two decades. It has been identified that approximately 70% of deaths from cancer occur in low- and middle-income countries. The growing incidence and prevalence of cancer and launch of novel cancer therapy, coupled with increasing awareness about cancer cure and treatment, are likely to drive the growth of the global cancer therapy market during the forecast period. Additionally, increasing Patient Assistance Programs (PAP’s), growing government initiatives for cancer awareness, and strong R&D Initiatives from key players are anticipated to drive the market for global cancer therapies.

High Cost of Cancer Therapies

The global cost of cancer therapy and drugs had increased from USD 91 billion to USD 113 billion in 2016.The US market is estimated to account for 46% of the global cancer cost. Factors, such as longer duration of cancer therapies, availability of novel agents, and use of combination therapy are contributing to the rising cost of cancer therapy. Additionally, cancer cost is expected to grow in the range of 6% to 9%, annually, during the forecast period. Thus, rising cost of cancer therapies, coupled with fluctuation of reimbursement policies for cancer treatment across the globe, is likely to impede the growth of the global cancer therapy market

North America to Dominate the Market

North America dominates the global cancer therapy market, owing to high prevalence of cancer in the region because of a sedentary lifestyle, along with launch and growing adoption of novel cancer therapy in the region.
Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of cancer, growing awareness regarding cure and treatment of cancer, and increasing collaboration between public and private sectors to provide novel cancer therapy in the region.

Key Developments in the Market

• February 2018: Bristol-Myers Squibb Company announced cancer deal with Nektar Therapeutics. As per the deal, Bristol-Myers Squibb Company will pay USD 1.85 billion to Nektar Therapeutics. The partnership is built around the Nektar drug, NKTR-214, which will be tested in combination with Bristol’s immuno-oncology (IO) drugs Opdivo and Opdivo and Yervoy in 20 cancer indications across nine different tumor types, including melanoma, kidney, and lung cancers
• January 2018: AstraZeneca and Merck & Co., Inc., received approval from US Food and Drug Administration, for Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.

Major Players: AMGEN, ASTRAZENECA, BRISTOL-MYERS SQUIBB, BAYER AG, F. HOFFMANN-LA ROCHE LTD, ELI LILLY, JOHNSON & JOHNSON, MERCK & CO. INC., NOVARTIS AG, AND PFIZER INC., among others.

Reasons to Purchase this Report

• Current and future global cancer therapies market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Patient Assistance Programs (PAP’s)
6.1.2 Growing Government Initiatives for Cancer Awareness
6.1.3 Rising Prevalence of Cancer Worldwide
6.1.4 Strong R&D Initiatives from Key Players
6.2 Market Restraints
6.2.1 Fluctuation in Reimbursement Policies
6.2.2 High Cost of Cancer Therapies
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Therapy Type
7.1.1 Chemotherapy
7.1.2 Targeted Therapy
7.1.3 Immunotherapy (Biologic Therapy)
7.1.4 Hormonal Therapy
7.1.5 Others
7.2 By Cancer Type
7.2.1 Blood Cancer
7.2.2 Breast Cancer
7.2.3 Prostate Cancer
7.2.4 Skin Cancer
7.2.5 Respiratory/Lung Cancer
7.2.6 Others
7.3 By End User
7.3.1 Hospitals
7.3.2 Specilty Clinics
7.3.3 Radiation Therapy Centers
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest Of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Amgen
9.2 AstraZeneca
9.3 Bayer AG
9.4 Bristol-Myers Squibb
9.5 F. Hoffmann-La Roche AG
9.6 Eli Lilly
9.7 Johnson & Johnson
9.8 Merck & Co. Inc
9.9 Novartis AG
9.10 Pfizer Inc.
9.11 Others
10. Future of the Market